Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules

Why It Matters

The omniDAWN accelerates high‑throughput biologics development and quality control, giving manufacturers faster, more accurate data on complex therapeutics without relying on calibration standards.

Key Takeaways

• omniDAWN extends MALS range to 500 nm radius
• Enables rapid UHPLC/UPLC analysis up to four times faster
• Reduces sample consumption by up to 50 % and solvent use 40 %
• Provides absolute molar mass without calibration standards
• Supports ADC, LNP, viral vector characterization for late‑stage development

Pulse Analysis

The launch of Waters' omniDAWN™ MALS photometer addresses a long‑standing gap in chromatographic detection for large‑molecule therapeutics. Traditional MALS detectors were limited to smaller particle sizes and struggled to keep pace with the high‑resolution separations offered by UHPLC and UPLC platforms. By expanding the detectable radius ten‑fold to 500 nm, omniDAWN enables reliable sizing of protein aggregates, viral vectors, and lipid nanoparticles—critical quality attributes for next‑generation biologics and nanomedicines. This broader range, coupled with 18 detection angles, delivers absolute molar mass data without the need for external calibration standards, simplifying method development and improving data confidence.

From an operational perspective, the instrument’s low‑dispersion design preserves chromatographic resolution while delivering run times up to four times faster than conventional HPLC‑based MALS workflows. Sample consumption drops by 30‑50 %, and solvent usage falls roughly 40 %, translating into lower operating costs and a smaller environmental footprint. For biopharma labs handling high‑throughput biosimilarity studies, ADC profiling, or viral vector analytics, these efficiencies can shave weeks off development timelines and free resources for additional experiments.

Strategically, omniDAWN positions Waters at the forefront of analytical technology for advanced therapeutics. Its compliance with 21 CFR Part 11 and EU Annex 11, along with upcoming integration with Empower™ software, ensures seamless adoption in regulated environments. As the market for mRNA vaccines, gene therapies, and nanocarrier‑based drugs expands, the ability to rapidly and accurately characterize large molecules will become a competitive differentiator, making omniDAWN a pivotal tool for both discovery and quality assurance.